Novartis halts development of experimental ALS drug after trial failure

Novartis has halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis (Lou Gehrig's disease), the latest in a long history of failed efforts to find a treatment for the condition. The halt follows a Phase 2 trial failure and marks the company's fourth clinical setback in three weeks.

Detected & updated continuously · Source: Nebula